Key terms
About LSTA
Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LSTA news
Yesterday
11:30am ET
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)
Apr 23
7:34am ET
Lisata, Qilu announce first patient treated in Phase 2 trial of LSTA1
Apr 17
4:12pm ET
Lisata Therapeutics Elevates James Nisco to Senior VP Finance
Mar 21
8:04am ET
Lisata Therapeutics announces U.S. FDA RPDD granted to LSTA1
Mar 01
6:16am ET
Lisata Therapeutics: A Strong Buy on Robust Clinical Progress and Solid Financial Footing
Feb 29
4:23pm ET
Lisata Therapeutics Announces Annual Financial Results
No recent press releases are available for LSTA
LSTA Financials
Key terms
Ad Feedback
LSTA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LSTA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
